Vivian Qin’s research aimed to improve outcomes for Hepatocellular Carcinoma (HCC) patients who do not respond to PD-1 immunotherapy. She developed a bispecific antibody targeting PD-L1 and IL-18, motivated by patient data showing these molecules’ role in resistance. Vivian encountered difficulties in antibody formation, but with her supervisor’s support and PolyU’s resources, she improved the binding ratio from 20% to 46%. The project provided valuable hands-on experience in mass spectrometry and antibody design, and taught Vivian to persist through setbacks. She developed patience, problem-solving skills, and the ability to collaborate effectively—qualities vital for success in biotech. Although the project continues in her supervisor’s lab, Vivian’s journey transformed her theoretical knowledge into practical expertise and gave her confidence to face future challenges in academia and industry.
